UAE's MGX Joins $2.1 Billion Funding Round for AI Drug Discovery Firm Isomorphic Labs

UAE-based MGX announced its participation in a massive $2.1 billion funding round for Isomorphic Labs, a company specializing in AI-powered drug discovery. This move highlights how sovereign wealth funds are increasingly betting on the 'smart biology' sector as one of the most prominent future applications of artificial intelligence. Isomorphic Labs, which spun out of Alphabet's DeepMind ecosystem, announced the closing of its Series B funding round, totaling $2.1 billion. This round saw participation from a group of leading global investors, including MGX, Thrive Capital, GV, Temasek, CapitalG, and the UK Sovereign AI Fund. This clearly shows the growing interest of sovereign capital in the 'bio-AI' sector. MGX's involvement is part of a broader strategy to boost its global presence in the artificial intelligence ecosystem. What's particularly interesting about this deal is that the investment wasn't directed towards traditional AI infrastructure like data centers, semiconductors, or language models. Instead, it focused on the more complex and sensitive area of drug discovery. This reflects a wider shift in how sovereign investors view AI. They see it as a strategic layer that can reshape vital sectors, from healthcare to pharmaceuticals, by integrating data with algorithms right at the heart of medical innovation. MGX: From Infrastructure to 'Smart Biological Infrastructure' Since its establishment, MGX has focused on investing in AI-related infrastructure, including advanced computing, data centers, and model technologies. However, the investment in Isomorphic Labs marks a clear expansion of this vision towards what we can call 'smart biological infrastructure.' Here, AI becomes a direct component in designing medicines and developing treatments. This reflects a growing belief that the future of the health sector won't just rely on traditional pharmaceutical companies or hospitals. Instead, it will depend on smart systems capable of analyzing molecules and proteins, and designing therapeutic compounds with greater accuracy and speed. Isomorphic Labs Isomorphic Labs is one of the prominent companies to emerge from Alphabet's DeepMind ecosystem. It's working on developing its own unique technical engine to use artificial intelligence for drug discovery. The company aims to completely re-engineer the drug development process using computational models. These models can predict biological interactions and design therapeutic compounds even before they enter traditional testing phases.